Published in final edited form as:

Curr Trop Med Rep. 2019 June ; 6(2): 50–54. doi:10.1007/s40475-019-00174-1.

Antibody immunity and natural resistance to cryptococcosis

N Trevijano-Contador¹ and L Pirofski^{1,2}

¹Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA

²Department of Microbiology & Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA.poly

Abstract

The encapsulated fungus *Cryptococcus neoformans* (Cn) causes cryptococcal meningitis (CM). There are ~180,000 deaths per year worldwide attributed to CM, which is the most common cause of meningitis in adults with HIV in sub-Saharan Africa. HIV infection with advanced immunodeficiency is the most important predisposing risk factor for CM, highlighting the critical role that T cell mediated immunity plays in disease prevention. Numerous studies in the past decade demonstrate that antibody immunity also plays a role in resistance to CM, although its role has taken more time to establish. In mice, B cells reduce early dissemination from lungs to brain, and naïve mouse IgM can enhance fungal containment in the lungs. In concert with these findings, human studies show that patients with CM have lower IgM memory B cell levels and/or different serological profiles than controls.

In this article, we review recent data on the role that B cells and/or antibody-based immunity play in host defense against Cn and natural resistance to CM.

Keywords

Cryptococcus neoformans; B-cells; antibodies; IgM; host immunity; adaptive response

Introduction

Cryptococcus neoformans (Cn) is an encapsulated basidiomycetes yeast widely distributed in the environment. It is the most common cause of meningitis in HIV-infected adults in sub-Saharan Africa, Asia and South America^{1, 2}. Cn is acquired by inhalation, makes the first stop in the lungs, colonizes this organ and in most people enters a state of latency^{3, 4}. In some people, mainly those with advanced immune suppression, Cn can disseminate to the central nervous system and cause meningoencephalitis, or cryptococcal meningitis (CM)². In 2014, it was estimated there were 215,000 cases and 180,000 deaths due to Cn worldwide⁵, primarily in HIV-infected persons. It is noteworthy that despite antiretroviral therapy (ART) roll out, the incidence of CM has not changed substantially in Africa or Asia^{5–7}.

B cells and resistance to CM: historical studies

As the HIV/AIDS pandemic unfolded and an unprecedented number of cases of CM occurred beginning in the 1980's, the link between CM and AIDS-associated CD4 T cell loss in patients established a role for T cells in resistance to CM. Studies in mice largely confirmed clinical observations in patients. On the other hand, a role for B cells was more difficult to establish. In part, this reflected an insufficient understanding that HIV infection also causes profound B cell defects. In addition, tools to study B cell effects in mice were limited. For example, one study did not reveal a difference in the susceptibility of B cell sufficient and B cell depleted mice to Cn⁸. In this study, newborn mice were rendered B cell deficient by administration of rabbit anti-mouse- μ antiserum prior to intravenous infection with Cn. There was no difference in mortality, colony forming units (CFUs) in different organs, or antigen level in the sera of control and B-cell-deficient animals. However, a subsequent study in a B cell knockout (uMT) mouse model showed these mice were more susceptible to Cn than wild type mice⁹. Notably, B cells were the predominant cell type in the lungs of A/JCr mice infected with Cn¹⁰, demonstrating they contribute to the immune response to Cn. These early studies suggested B cells can enhance natural immunity and resistance to Cn.

Many studies dating to over 40 years ago show that administration of immune sera containing glucuronoxylomannan (GXM) capsular polysaccharide specific antibodies elicited by vaccination can protect naïve mice against Cn^{11, 12}. Extensive work with monoclonal GXM antibodies showed that they can be protective, non-protective, or detrimental depending on isotype, specificity, and host factors¹². These elegant studies revealed that the effect of specific IgG (or IgM) elicited by an acquired antibody response on the outcome of Cn infection is highly complex. One important study showed B cells were an important component of acquired resistance to Cn¹³. In this model, although Cn-infected μ Mt knock out (B cell deficient) mice developed an immune response that protected them against CM, SCID mice reconstituted with lymphocytes from these mice had high fungal burdens, failed to contain Cn, and had reduced survival, whereas mice reconstituted with lymphocytes from B cell-sufficient mice had lower lung and brain CFU. Thus, B cells contributed to control of Cn when T-cell-mediated immunity was impaired¹³. This scenario resembles the immune status of patients with HIV/AIDS, whereby profound T cell loss occurs in the setting of marked B cell defects^{14, 15}. Of note, a vaccine-elicited GXM IgG1 produced excessive lung inflammation and did not protect uMt mice from lethal Cn, suggesting that normal B cells and/or natural antibodies have a role in regulating inflammation stemming from antibody-mediated immunity to Cn⁹. Overall, these studies showed that administration of defined antibodies formed during an acquired immune response to Cn mediate protection against CM. However, they did not address the role that B cells or antibody may play in natural resistance to Cn.

B cells and their role in natural resistance to Cn

Mice, like humans are highly resistant to Cn; infection is common, disease is rare^{3, 4}. In the past 10 years, numerous studies investigated the role that B cells play in natural resistance to CM in mice^{16–19}. One study showed that B-1 and B-2 cells each contribute to the early

immune response to Cn¹⁷. In this model, capsular and acapsular Cn bound to B-1 cells. B-1a cells were required for early Cn clearance from the lungs; they enhanced Cn phagocytosis and reduced dissemination to the brain¹⁷. This revealed a new paradigm to understand how B cells may augment host defense against Cn. In contrast to prior work that sought to establish a role for B cells and/or antibody in acquired immunity to Cn (see above), this study showed that B-1a cells are a key contributor to the early innate mouse immune response to Cn. In another study, the role of B-1 cells in resistance to intranasal infection with Cn was examined in X-linked immunodeficient (XID) mice¹⁹. XID mice, which have a mutation in the Bruton's tyrosine kinase (Btk) gene in B cells²⁰, lack B-1 cells and have reduced levels of natural IgM. These mice had higher lung and brain CFU than controls three weeks after infection¹⁹. Lung Cn phagocytosis was impaired and histopathology revealed a diffuse, disorganized inflammatory pattern with significantly more enlarged extracellular Cn. In contrast, control mice had numerous small, intracellular yeast cells¹⁹. This finding was of interest, because Cn can undergo morphological changes that result in the formation of Titan cells, which have enhanced virulence^{21–24}. A Cn infection model in Rag1^{−/−} mice showed that these mice, which lack B and T cells¹⁶, exhibited earlier and more Cn dissemination to the brain than wild-type mice. Adoptive transfer of wild-type B cells to these mice led to reduced brain CFU and reversal of an abnormal inflammatory lung histopathology pattern to one that resembled the wild-type response.

How might B cells augment natural resistance to experimental CM?

Several hypotheses may explain how B cells enhance resistance to CM. One is that they help curtail Cn dissemination. This may be mediated by the antibodies they produce. B-1 cells mainly produce IgM. B-1 and B-2 cells each produce IgM in the early innate immune response to Cn that binds GXM and Laminarin (Lam, a mainly 1,3-β-glucan)¹⁷. Multiple studies now show IgM enhances early resistance to Cn dissemination in mice^{16, 18}. IgM can also augment macrophage recruitment and phagocytosis of Cn^{18, 25}. Therefore, naïve IgM may enhance early antifungal immunity in the lungs¹⁶. This was examined in sIgM^{−/−} mice, which lack secreted IgM. In this model, lung CFUs were similar in sIgM^{−/−} and control mice after intranasal infection with Cn, but mortality was higher in sIgM^{−/−} mice and they had higher brain CFU and marked brain inflammation¹⁸. Adoptive transfer of IgM restored control levels of Cn alveolar macrophage phagocytosis.

As noted above, adoptive transfer of B cells reduced Cn dissemination from lungs to brain in Rag1^{−/−} mice¹⁶. Transfer of naïve IgM from wild-type mice in the same model enhanced alveolar macrophage phagocytosis of Cn. Taken together, these studies establish that B cells and/or their secreted product, IgM, enhance early innate immunity to Cn in the lungs of mice. Given that naïve IgM enhanced Cn phagocytosis in multiple models, e.g. (wild-type, sIgM^{−/−}, and Rag1^{−/−} mice), it is logical to posit it contains antibodies that bind Cn determinants that augment phagocytosis and/or other host defense mechanisms in the lungs. Consistent with this idea, naïve IgM enhanced host defense against pneumocystis in mice via antibodies that reacted with beta glucans²⁵. Thus, B cells and/or naïve IgM reduce early Cn dissemination, making them a component of the early innate immune response to Cn in the lungs.

Another mechanism by which IgM could enhance resistance to Cn is by restricting fungal size in the lungs and promoting fungal containment. Though this remains a hypothesis, it is reasonable to posit that absence of IgM in the lungs may have contributed to Cn enlargement in XID mice¹⁹, possibly inhibiting Titan cell formation. In support of this idea, a mouse 1,3- β -glucan-binding IgG2b (2G8) isolated from a Lam-vaccinated mouse bound the Cn cell wall, mediated non-opsonic Cn killing *in vitro*, protected mice against lethal Cn challenge²⁶. Cn isolated from lungs and brain of 2G8-treated mice were smaller than those in control mice, suggesting the antibody may have inhibited Titan cell formation.

Translating knowledge gained from mice to humans

Numerous serological studies dating to the mid-1990's have demonstrated differences, often featuring lower levels of GXM-IgM, between the GXM antibody profiles of HIV-infected persons, HIV-infected persons with a history of CM, and HIV-uninfected controls^{27–31}. These studies linked perturbations in GXM antibody repertoires with HIV infection and CM. However, differences were not limited to those with HIV infection; a study of HIV-uninfected solid organ transplant (SOT) recipients showed pre-transplant levels of GXM-IgM were lower in those who developed CM post-transplant than those who did not³². Since IgM memory (CD10+CD27+IgM+) B cells (see³¹) which resemble B-1 cells in mice³³, are the source of ~ 50% circulating IgM and are depleted in HIV infection^{14, 31}, perturbations in IgM may be due to a B cell repertoire defect.

Links between IgM memory B cell levels and risk for CM

Consistent with studies in mice linking B-1 cells to resistance to Cn dissemination, an association between lower levels of peripheral IgM memory B cells and HIV-associated CM was identified in two cohorts³¹: 1) HIV-infected persons with a past history of CM and HIV-infected persons with no history of CM (retrospective cohort); and 2) HIV-infected males in the multicenter AIDS cohort study (MACS) who subsequently developed CM and those who did not, matched for CD4 T cell count (> 300 cells/ul, prospective cohort). Persons in both cohorts who had/or developed CM had lower levels of memory (CD19+CD27+) and IgM memory B cells than those with no history of or who did not develop CM. A similar study with a cohort of HIV-uninfected persons with and without CM had similar findings; those with a history of CM had lower levels of memory and IgM memory B cells than those who did not³⁴. CD4 T cell levels were statistically comparable and CD8 T cell levels were numerically, but not statistically significantly so in those who developed CM. X-linked hyper IgM (XHIM), which is marked by elevated serum IgM, low IgG levels and reduced levels of IgM memory B cells, has also been associated with cryptococcosis in children³⁵. A mutation in the Bruton tyrosine kinase is the cause of X-linked agammaglobulinemia³⁶, and as above, XID mice are more susceptible to Cn dissemination. Notably, cases of CM are increasingly reported in adult patients treated with the Bruton tyrosine kinase inhibitor, ibrutinib^{37–39,40, 41}.

Links between IgM and natural antibodies and risk for CM

IgM memory B cells produce ~ 50% of the IgM in human sera³³. Human serum IgM and IgG bind carbohydrate and polysaccharide Ags, including β -glucans, conserved fungal determinants found on Cn and many other fungi⁴². For example, human sera from HIV-infected patients with CM bound to glycosylated determinants on the Cn cell wall and inhibited its growth⁴³.

Two recent studies examined levels of Cn and Lam (β -glucan) binding antibodies in persons at risk for and with CM^{44, 45}. Normal human serum antibodies bind Lam, a branched (mainly) 1, 3- β -glucan⁴². One study compared HIV-infected persons with positive or negative serum assays for cryptococcal antigen (CrAg)⁴⁵. CrAg positive persons are at high risk for CM⁴⁶. The results showed that Lam-binding-IgM and IgG were lower in CrAg positive persons and negatively correlated with CrAg positive status. Using an iterative statistical model, this study found that in combination, plasma IgG2, IgM, GXM-IgG, Lam-IgM, and Lam-IgG had an 80% ability to predict CrAg positive status. This suggests statistical modeling may hold promise for identifying serological biomarkers of risk for CM. In another study, plasma levels of IgM, GXM-IgM and Lam-binding-IgM were lower in HIV-infected patients who developed cryptococcal-immune reconstitution inflammatory syndrome (C-IRIS) after ART initiation⁴⁴. These findings suggest β -glucan-binding antibodies may have a role in preventing CM and/or the inflammatory manifestations of C-IRIS, and may also hold promise as biomarkers of risk for C-IRIS. Since β -D-glucan (BDG) levels may be elevated in patients with CM⁴⁷, associations between lower levels of Lam antibodies, CM and C-IRIS, suggest these antibodies may play a role in controlling BDG-mediated inflammation. Finally, we note that multiple studies show that serum levels of GXM-IgG are higher in HIV-infected persons, those with a history of CM, and those with positive CrAg assays than controls^{27, 28, 34}. These data suggest the hypothesis that GXM-IgG levels may reflect fungal burden, an idea that requires further study.

Conclusion

While recognition of the role that cell mediated immunity plays in resistance to CM is longstanding, particularly in HIV-infected persons, ample data now show B cells also contribute to resistance to CM in mice and may play a similar role in humans. In mice, B cells and naïve IgM enhance immunity to Cn in the lungs. In humans, lower levels of IgM memory B cells associate with CM in HIV-infected and HIV-uninfected persons, and lower levels of GXM-IgM, Lam(β -glucan)-binding IgM and IgG can associate with HIV-associated CM, risk for CM, and/or C-IRIS. These findings require validation in larger, racially diverse cohorts, and statistical modeling may help identify robust serological markers. Nonetheless, available data point to a possible role for B cells and certain antibodies in natural resistance to CM and underscore the need for a deeper understanding of mechanisms by which natural and Cn-binding antibodies may reduce Cn virulence and protect against Cn dissemination and human CM.

Acknowledgements

Liise-anne Pirofski was supported in part by NIH grant AI097096.

References

Papers of particular interest, published recently, have been highlighted as:

• Of importance

•• Of major importance

1. Lazera MS, Salmito Cavalcanti MA, Londero AT, Trilles L, Nishikawa MM, Wanke B. Possible primary ecological niche of *Cryptococcus neoformans*. *Medical mycology* 2000; 38:379–83. [PubMed: 11092385]
2. Casadevall A, Perfect J. *Cryptococcus neoformans*. Washington DC: ASM, 1998.
3. Rohatgi S, Pirofski LA. Host immunity to *Cryptococcus neoformans*. *Future Microbiol* 2015; 10:565–81. [PubMed: 25865194]
4. Pirofski LA, Casadevall A. Immune-Mediated Damage Completes the Parabola: *Cryptococcus neoformans* Pathogenesis Can Reflect the Outcome of a Weak or Strong Immune Response. *mBio* 2017; 8.
5. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. *Lancet Infect Dis* 2017; 17:873–81 [PubMed: 28483415] * Provides a circa 2014 estimate of the global incidence of HIV-associated cryptococcal disease, HIV incidence, ART access, and retention in care using published UNAIDS and cryptococcal prevalence data.
6. Shaheen AA, Somayaji R, Myers R, Mody CH. Epidemiology and trends of cryptococcosis in the United States from 2000 to 2007: A population-based study. *Int J STD AIDS* 2018; 29:453–60.
7. Enoch DA, Yang H, Aliyu SH, Micallef C. The Changing Epidemiology of Invasive Fungal Infections. *Methods Mol Biol* 2017; 1508:17–65. [PubMed: 27837497]
8. Monga DP, Kumar R, Mohapatra LN, Malaviya AN. Experimental cryptococcosis in normal and B-cell-deficient mice. *Infection and immunity* 1979; 26:1–3. [PubMed: 387600]
9. Rivera J, Casadevall A. Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against *Cryptococcus neoformans*. *Journal of immunology* 2005; 174:8017–26.
10. Feldmesser M, Mednick A, Casadevall A. Antibody-mediated protection in murine *Cryptococcus neoformans* infection is associated with pleiotropic effects on cytokine and leukocyte responses. *Infection and immunity* 2002; 70:1571–80. [PubMed: 11854246]
11. Datta K, Pirofski LA. Towards a vaccine for *Cryptococcus neoformans*: principles and caveats. *FEMS yeast research* 2006; 6:525–36. [PubMed: 16696648]
12. Casadevall A, Pirofski L. Insights into mechanisms of antibody-mediated immunity from studies with *Cryptococcus neoformans*. *Current molecular medicine* 2005; 5:421–33. [PubMed: 15977998]
13. Aguirre KM, Johnson LL. A role for B cells in resistance to *Cryptococcus neoformans* in mice. *Infection and immunity* 1997; 65:525–30. [PubMed: 9009308]
14. Moir S, Fauci AS. B cells in HIV infection and disease. *Nature reviews Immunology* 2009; 9:235–45.
15. Lane HC, Shelhamer JH, Mostowski HS, Fauci AS. Human monoclonal anti-keyhole limpet hemocyanin antibody-secreting hybridoma produced from peripheral blood B lymphocytes of a keyhole limpet hemocyanin-immune individual. *The Journal of experimental medicine* 1982; 155:333–8. [PubMed: 6976416]
16. Dufaud C, Rivera J, Rohatgi S, Pirofski LA. Naive B cells reduce fungal dissemination in *Cryptococcus neoformans* infected Rag1(–/–) mice. *Virulence* 2018; 9:173–84 [PubMed: 28837391] ** This article establishes that B cells are able to reduce early Cn dissemination in mice and suggest that normal mouse IgM may be a key mediator of early antifungal immunity in the lungs.
17. Rohatgi S, Pirofski LA. Molecular characterization of the early B cell response to pulmonary *Cryptococcus neoformans* infection. *Journal of immunology* 2012; 189:5820–30.

18. Subramaniam KS, Datta K, Quintero E, Manix C, Marks MS, Pirofski LA. The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with *Cryptococcus neoformans*. *Journal of immunology* 2010; 184:5755–67* This paper shows that presence of normal mouse IgM reduces Cn dissemination to the brain, promotes containment of Cn in the lungs, and enhances the phagocytic capacity of alveolar macrophages.
19. Szymczak WA, Davis MJ, Lundy SK, Dufaud C, Olszewski M, Pirofski LA. X-linked immunodeficient mice exhibit enhanced susceptibility to *Cryptococcus neoformans* infection. *mBio* 2013; 4:e00265–13 [PubMed: 23820392] * This paper shows that XID mice, which lack B-1 cells and IgM, exhibit a dissemination phenotype whereby Cn disseminates from lungs to brain, and suggests that absence of IgM impairs Cn phagocytosis and allows Cn enlargement in the lungs.
20. Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L, et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. *Science* 1993; 261:358–61. [PubMed: 8332901]
21. Trevijano-Contador N, Rueda C, Zaragoza O. Fungal morphogenetic changes inside the mammalian host. *Seminars in cell & developmental biology* 2016; 57:100–9. [PubMed: 27101887]
22. Trevijano-Contador N, de Oliveira HC, Garcia-Rodas R, Rossi SA, Llorente I, Zaballos A, et al. *Cryptococcus neoformans* can form titan-like cells in vitro in response to multiple signals. *PLoS pathogens* 2018; 14:e1007007 [PubMed: 29775477] * Provides a new method to investigate Titan cell formation in vitro. This method will make it possible to examine the effect of antibodies on Cn Titan cell formation.
23. Zaragoza O, Garcia-Rodas R, Nosanchuk JD, Cuenca-Estrella M, Rodriguez-Tudela JL, Casadevall A. Fungal cell gigantism during mammalian infection. *PLoS pathogens* 2010; 6:e1000945. [PubMed: 20585557]
24. Okagaki LH, Wang Y, Ballou ER, O'Meara TR, Bahn YS, Alspaugh JA, et al. Cryptococcal titan cell formation is regulated by G-protein signaling in response to multiple stimuli. *Eukaryotic cell* 2011; 10:1306–16. [PubMed: 21821718]
25. Rapaka RR, Ricks DM, Alcorn JF, Chen K, Khader SA, Zheng M, et al. Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus *Pneumocystis murina*. *The Journal of experimental medicine* 2010; 207:2907–19. [PubMed: 21149550]
26. Rachini A, Pietrella D, Lupo P, Torosantucci A, Chiani P, Bromuro C, et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of *Cryptococcus neoformans in vitro* and exerts therapeutic, anticryptococcal activity *in vivo*. *Infection and immunity* 2007; 75:5085–94. [PubMed: 17606600]
27. Fleuridor R, Lyles RH, Pirofski L. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without *Cryptococcus neoformans* meningitis. *The Journal of infectious diseases* 1999; 180:1526–35. [PubMed: 10515812]
28. Subramaniam K, French N, Pirofski LA. *Cryptococcus neoformans*-reactive and total immunoglobulin profiles of human immunodeficiency virus-infected and uninfected Ugandans. *Clin Diagn Lab Immunol* 2005; 12:1168–76. [PubMed: 16210479]
29. Deshaw M, Pirofski LA. Antibodies to the *Cryptococcus neoformans* capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals. *Clin Exp Immunol* 1995; 99:425–32. [PubMed: 7882565]
30. Abadi J, Pirofski L. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. *The Journal of infectious diseases* 1999; 180:915–9. [PubMed: 10438394]
31. Subramaniam K, Metzger B, Hanau LH, Guh A, Rucker L, Badri S, et al. IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status. *The Journal of infectious diseases* 2009; 200:244–51 [PubMed: 19527168] ** This paper shows that in a prospective and a retrospective cohort, levels of IgM memory B cells were lower in HIV-infected persons with than without a history of CM, suggesting the hypothesis that reduced levels of IgM memory B cells may portend risk for development of CM.

32. Jalali Z, Ng L, Singh N, Pirofski LA. Antibody response to *Cryptococcus neoformans* capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation. Clin Vaccine Immunol 2006; 13:740–6. [PubMed: 16829610]
33. Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunological reviews 2004; 197:179–91. [PubMed: 14962195]
34. **Rohatgi S, Nakouzi A, Carreno LJ, Slosar-Cheah M, Kuniholm MH, Wang T, et al. Antibody and B Cell Subset Perturbations in Human Immunodeficiency Virus-Uninfected Patients With Cryptococcosis. Open forum infectious diseases 2018; 5:ofx255. [PubMed: 29354657]
35. Jo EK, Kim HS, Lee MY, Iseki M, Lee JH, Song CH, et al. X-linked hyper-IgM syndrome associated with Cryptosporidium parvum and Cryptococcus neoformans infections: the first case with molecular diagnosis in Korea. Journal of Korean medical science 2002; 17:116–20. [PubMed: 11850600]
36. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993; 361:226–33. [PubMed: 8380905]
37. Arthurs B, Wunderle K, Hsu M, Kim S. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respiratory medicine case reports 2017; 21:27–9. [PubMed: 28377877]
38. Baron M, Zini JM, Challan Belval T, Vignon M, Denis B, Alanio A, et al. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Leukemia & lymphoma 2017; 58:2981–2. [PubMed: 28554246]
39. Ruchlemer R, Ben Ami R, Lachish T. Ibrutinib for Chronic Lymphocytic Leukemia. N Engl J Med 2016; 374:1593–4.
40. Chamilos G, Lionakis MS, Kontoyiannis DP. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018; 66:140–8. [PubMed: 29029010]
41. Messina JA, Maziarz EK, Spec A, Kontoyiannis DP, Perfect JR. Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib. Open forum infectious diseases 2017; 4:ofw261. [PubMed: 28480254]
42. Chiani P, Bromuro C, Cassone A, Torosantucci A. Anti-beta-glucan antibodies in healthy human subjects. Vaccine 2009; 27:513–9. [PubMed: 19041357]
43. Rodrigues ML, Travassos LR, Miranda KR, Franzen AJ, Rozental S, de Souza W, et al. Human antibodies against a purified glucosylceramide from *Cryptococcus neoformans* inhibit cell budding and fungal growth. Infection and immunity 2000; 68:7049–60. [PubMed: 11083830]
44. Yoon HA, Nakouzi A, Chang CC, Kuniholm MH, Carreno LJ, Wang T, et al. Association between plasma antibody responses and risk for *Cryptococcus*-associated immune reconstitution inflammatory syndrome. The Journal of infectious diseases 2018; ** This study shows plasma antibody profiles differ in HIV-infected patients with and without cryptococcal immunoreconstitution inflammatory syndrome (C-IRIS), and that levels of IgM, Lam-IgM, Lam-IgG, and/or GXM-IgM are lower in patients with than without CIRIS, suggesting these antibodies may play a role in controlling C-IRIS-associated inflammation.
45. Hlupeni A, Nakouzi A, Wang T, Boyd KF, Makadzange TA, Ndhlovu CE, et al. Antibody Responses in HIV-Infected Patients With Advanced Immunosuppression and Asymptomatic Cryptococcal Antigenemia. Open forum infectious diseases 2019; 6:ofy333. [PubMed: 30648127]
46. Longley N, Jarvis JN, Meintjes G, Boule A, Cross A, Kelly N, et al. Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; 62:581–7. [PubMed: 26565007]
47. Rhein J, Bahr NC, Morawski BM, Schutz C, Zhang Y, Finkelman M, et al. Detection of High Cerebrospinal Fluid Levels of (1->3)-beta-d-Glucan in Cryptococcal Meningitis. Open forum infectious diseases 2014; 1:ofu105. [PubMed: 25734173]